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CBT.Conclusion:These results strongly suggested that unrelated
CBT could be safely used for adult patients with hematological
malignancies.
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Uncertainty still exists with the effects of allogeneic PBSCT on
the clinical outcomes of patients with hematological malignancies.
Our aim was analyzed retrospectively the clinical outcomes of 483
patients who underwent an allo PBSCT in 9 Brazilian centers from
May 1994 to February 2004. The analyses included patients with
hematological malignancies who underwent PBSCT from HLA
identical sibling donors. Median age was 34 (2–57), advanced
disease was present in 58%, conditioning without irradiation was
85%; GVHD prophylaxis with MTX/CsA was 91%; CD34 me-
dian was 4.7  106/kg (0.51–71.6); the median follow-up for
surviving patients was 797 days (8–3420); median day for neutro-
phils and platelets engraftment was 15 and 14, respectively; cumu-
lative incidence (CI) for 3 2 aGVHD was 38%; extensive cGVHD
63%; CI for transplant relate mortality (TRM) 59%; CI for relapse
37%; the estimates of OS and DFS at 9 ys are 33% and 42%,
respectively. In univariate analyses the following factors were as-
sociated with better outcome: for neutrophils and platelets engraft-
ment- CD34 cell dose 2.8 106/kg, GVHD prophylaxis other
than MTX/CsA, and sex match other than female donor for male
recipient; aGVHD- age 
43, and CD34 dose 4.7  106/kg;
cGVHD- age 
25 ys, sex match other than female donor for male
recipient, advanced disease and CD3 dose 
170  106/kg; OS-
early disease; DFS- early disease, and CD34 dose 4.7  106/kg;
relapse- age 25 ys, CD34 cell dose 2.8  106/kg, and early
disease; TRM- early disease. All the results remained signiﬁcant in
multivariate analyses, but for CD34 dose and platelet engraft-
ment; age and CD34 dose in aGVHD; age and CD3 in
cGVHD, and age in relapse. In our experience, sex match, CD34
dose, GVHD prophylaxis may inﬂuence the engraftment, and sex
match and disease phase the cGVHD. Furthermore, advanced
disease had a negative impact on OS and TRM. CD34 higher
dose and early disease were associated with better DFS and lower
relapse.
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Graft failure is associated with a high mortality rate. To date,
regimens invoked for secondary transplants have resulted in incon-
sistent engraftment with high transplant-related mortality. We
here report 15 patients, aged 4–59 years (median 24 years), who
received secondary HSCT (HSCT-2) following rejection of pri-
mary unmodiﬁed (N4) or T-cell depleted (N11) HSCT
(HSCT-1). HSCT-1 included myeloablative TBI- or alkylator-
based conditioning for acute leukemias (N5), MDS (N6), CML
(N3), and Fanconi anemia (N1). Cytoreduction regimens used
for HSCT-2 included: Fludarabine (Flu) alone (N2) or in com-
bination with Cyclophosphamide (CTX) (N8) or Thiotepa
(Thio) (N4), or Thio combined with CTX (N1). ATG (N11)
or Alemtuzumab (N3) was added pretransplant to prevent rejec-
tion. For HSCT-2, donors included: HLA-matched (N3) or
non-identical (N7) relatives and matched (N1) or non-identical
(N4) unrelated donors. The primary graft donor was used in
seven of ﬁfteen cases. The grafts administered were unmodiﬁed
PBSCT (N6) or BMT (N2) or T-cell depleted (TCD) PBSCT
(N7). Of 15 patients, 14 achieved engraftment with complete
chimerism. Mean time to engraftment (ANC 1000 for 3 days)
was 15.4 days. Seven patients died of infection (N5), graft failure
(N1), or encephalopathy (N1) within 100 days post-transplant,
and four patients succumbed to GVHD (N1), relapse (N1),
pneumonia (N1), or EBV lymphoma (N1) 6–15 months post-
transplant. Four patients are alive and disease-free with a median
follow-up of 51 months, including 3/8 conditioned with Flu/CTX.
In this limited series, younger patients (4/7
 20 years vs. 0/8 20
years), transplants from secondary donors (3/8 with secondary
donor vs. 1/7 with primary donor), and TCD HSCT-2 (3/7 TCD
vs. 1/8 unmodiﬁed) had a better outcome. In summary, secondary
HSCT following a Flu/ATG-based non-myeloablative regimen
have achieved consistent engraftment with hematopoietic recon-
stitution in patients with a primary graft failure, but are limited by
infections complicating delayed immune reconstitution.
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For patients (pts) with Non-Hodgkin’s Lymphoma (NHL), the
optimal timing and conditioning regimen intensity for transplant
has not been deﬁned. Nonmyeloablative stem cell transplants
(NMT) have been reserved for those patients at high risk for
treatment related morbidity and mortality (TRM) from conven-
tional High Dose allogeneic SCT (HDT) and have been increas-
ingly employed as salvage therapy for relapse after autotransplan-
tation. To assess the effectiveness of this approach, we performed
a retrospective analysis of 35 pts who have undergone either HDT
(n20) with a TBI-based regimen or NMT (n15) with a ﬂudara-
bine-based regimen followed by allogeneic SCT for high risk
NHL. Stem cell source varied by conditioning; 13/15 of HDT pts
received bone marrow (11 sib, 2 MUD), while all NMT pts
received peripheral blood (11 sib, 9 MUD). NMT pts constituted
a higher risk cohort based on extent of prior therapy (including
80% s/p autotransplant), chemoresistance, and age. Distribution of
histology for the entire group was skewed toward aggressive his-
tology, but equally distributed between HDT and NMT. For pts
surviving 90 days, median follow up for HDT pts is 50 months
(4–92 m), vs 12 months (4–45 m) for NMT pts. A comparison of
overall survival (53 vs 45%), event-free survival (53 vs 48%), and
progression-free survival (88 vs 64%) at 1 year demonstrated no
signiﬁcant differences between HDT and NMT cohorts despite
the higher risk nature of the NMT group. The 100-day TRM for
HDT vs NMT pts was similar (33 vs 30%, pns). The incidence
of grade II-IV acute GvHD was not signiﬁcantly different between
HDT (3/13 evaluable, 23%) and NMT (7/20, 35%). Among evalu-
able pts, chronic GvHD was lower in the HDT group vs NMT (13
vs 50%). Among causes of death, disease-related deaths were lower
in the HDT group (1/7, 14%) compared with NMT pts (5/11,
45%). This retrospective analysis demonstrates 1) NMT induces
durable remissions in a signiﬁcant number of poor risk pts; 2)
outcomes after NMT may be comparable to HDT; 3) relapse rates
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